Reversal of Anticoagulant Effects in Patients with Intracerebral Hemorrhage
- 688 Downloads
Anticoagulant therapies are increasingly being used for the treatment and prevention of thromboembolic diseases. A growing incidence of anticoagulant-associated intracranial hemorrhage (AICH) has accompanied the rise in their use. Although the rate of intracerebral hemorrhage (ICH) in patients receiving anticoagulation therapies such as heparin and target-specific oral anticoagulants (TSOAs) is significantly lower than that of vitamin K antagonists (VKAs), the mortality rate remains high. TSOAs have only recently become available for use in clinical practice, and presently, there is a paucity of both clinical data and evidence-based guidelines to assist in the management of TSOA-associated intracerebral hemorrhage. In this article, we review current literature and provide physicians with diagnostic and therapeutic considerations for the management of AICH.
KeywordsAnticoagulants Apixaban Dabigatran Intracerebral hemorrhage Target-specific oral anticoagulants Prothrombin complex concentrate Rivaroxaban Vitamin K Warfarin
Compliance with Ethics Guidelines
Conflict of Interest
Sean Yates declares no conflict of interest.
Ravi Sarode is a consultant for CSL Behring and Octapharma.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 12.Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465–70.PubMedCrossRefGoogle Scholar
- 14.•Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e152S–84. The most recent guidelines from the American College of Chest Physicians summarizing recommendations for the management of antithrombotic therapy.Google Scholar
- 16.••Sarode R, Milling TJ, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128:1234–43. A randomized multicenter trial investigating the safety and efficacy of 4F-PCC for patients with warfarin-associated coagulopathy. Trial results led to the approval of 4F-PCC in the United States for urgent warfarin reversal.PubMedGoogle Scholar
- 19.•Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013;70:1486–90. A meta-analysis of randomized clinical trials evaluating the incidence of intracranial hemorrhage in patients receiving warfarin and TSOAs.PubMedGoogle Scholar
- 27.•Kitchen S, Gray E, Mackie I, Baglin T, Makris M, committee the B. Measurement of non-Coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol. 2014;166:830–41. The most recent guidelines from the British Committee for Standards in Haematology characterizing appropriate tests for evaluating the effects of non-Coumarin anticoagulants.PubMedCrossRefGoogle Scholar
- 29.Mueck W, Lensing AWA, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50:675–86.PubMedCrossRefGoogle Scholar
- 30.•Bowry R, Fraser S, Archeval-Lao JM, Parker SA, Cai C, Rahbar MH, et al. Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke. Stroke. 2014;45:880–3. This article characterizes the use of thrombelastography to detect the anticoagulant effects of rivaroxaban in patients presenting with ischemic stroke.PubMedCrossRefGoogle Scholar
- 31.•Adelmann D, Marion W, Wohlgemuth RK, Koch S, Frantal S, Quehenberger P, et al. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. Thromb Res. 2014;134(4):918–23. This article characterizes the use of rotational thrombelastography for detecting anticoagulant effects in patients receiving varying doses of either rivaroxaban or apixaban. PubMedCrossRefGoogle Scholar
- 34.••Tazarourte K, Riou B, Tremey B, Samama C-M, Vicaut E, Vigué B. Guideline-concordant administration of prothrombin complex concentrate and vitamin K is associated with decreased mortality in patients with severe bleeding under vitamin K antagonist treatment (EPAHK study). Crit Care. 2014;18:R81. A prospective observational study of patients presenting with vitamin K-antagonist-associated severe bleeding, demonstrating that administration of vitamin K and PCC within 8 h of presentation resulted in a threefold decrease in the 7-day mortality of ICH.PubMedCentralPubMedCrossRefGoogle Scholar
- 40.Tran HA, Chunilal SD, Harper PL, Tran H, Wood EM, Gallus AS. An update of consensus guidelines for warfarin reversal. Med J Aust. 2013;198:1–7.Google Scholar
- 43.••Zhou W, Zorn M, Nawroth P, Bütehorn U, Perzborn E, Heitmeier S, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke. 2013;44:771–8. This article characterizes an experimental mouse model of rivaroxaban-associated cerebral hemorrhage and the effects of various hemostatic agents on intracerebral hematoma expansion.PubMedCrossRefGoogle Scholar
- 46.•Dickneite G, Hoffman M. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? Thromb Haemost. 2014;111:189–98. This article provides a comprehensive review of data regarding the use of PCC for reversing the anticoagulant effects of TSOAs.PubMedCrossRefGoogle Scholar
- 53.••Schiele F, Van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–62. This article characterizes the first specific antidote for dabigatran, aDabi-Fab, demonstrating reversal of the anticoagulant effects in human plasma in vitro and in rats in vivo.PubMedCrossRefGoogle Scholar
- 54.••Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446–51. This article characterizes the study of a specific antidote for factor Xa inhibitors, andexanet alfa, demonstrating its ability to reverse the anticoagulant effects of both fondaparinux and enoxaparin.PubMedCrossRefGoogle Scholar
- 55.Carr JA, Silverman N. The heparin-protamine interaction. A review. J Cardiovasc Surg (Torino). 1999;40:659–66.Google Scholar